<track id="zpztl"><span id="zpztl"></span></track>
<big id="zpztl"></big>

<p id="zpztl"></p><dfn id="zpztl"><address id="zpztl"></address></dfn>

<font id="zpztl"></font>
<address id="zpztl"><span id="zpztl"></span></address>

    <pre id="zpztl"></pre>

    <p id="zpztl"></p>

    <th id="zpztl"></th>

      <dfn id="zpztl"><mark id="zpztl"></mark></dfn>
      歡迎光臨~杭州紐羅西敏生物科技有限公司
        咨詢電話:0571-88254427

      行業新聞及文獻

      Evidence of recent Epstein-Barr virus reactivation in individuals experiencing Long COVID

      Epstein-Barr virus (EBV) reactivation has been proposed as a driver of Long COVID (LC), but studies in well-characterized post-acute COVID-19 cohorts of individuals with and without Long COVID symptoms over a time course consistent with current case definitions of LC are limited. In a cohort of 294 hundred adults with a history of SARS-CoV-2 infection, we observed that LC symptoms such as fatigue and neurocognitive dysfunction at a median of 4 months following initial diagnosis were associated with serological evidence of recent EBV reactivation (early antigen-D IgG positivity or nuclear antigen IgG levels >600 U/mL), but not with ongoing EBV viremia.. Importantly, Long COVID was also observed in the small proportion without evidence of prior or recent EBV infection, suggesting that EBV reactivation is not a prerequisite for this condition. Overall, these findings expand our knowledge of the relationships between EBV reactivation and LC and suggest that further assessment during the acute phase of COVID-19 is warranted.

      聯系我們

      聯系人:

      手 機:0571-88254427

      郵 箱:info@neuro-hemin.com

      公 司:杭州紐羅西敏生物科技有限公司

      地 址:杭州市教工路316號

      <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <文本链> <文本链> <文本链> <文本链> <文本链> <文本链>